Programmed death ligand 2 in cancer-induced immune suppression

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Rozali, Esdy N ^a   Hato, Stanleyson V ^b   Robinson, Bruce W ^a,c   Lake, Richard A ^a,c   Lesterhuis, W Joost ^a,d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 LIGAND 2 BLOCKING ANTIBODY; STAT6 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NEOPLASM; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR IMMUNOLOGY; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MOLECULARLY TARGETED THERAPY; MOUSE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSION; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84861064002     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/656340     Document Type: Review

References (78)

1. Nurieva R. I., Liu X., Dong C., Yin-Yang of costimulation: crucial controls of immune tolerance and function Immunological Reviews 2009 229 1 88 100
2. Zou W., Chen L., Inhibitory B7-family molecules in the tumour microenvironment Nature Reviews Immunology 2008 8 6 467 477 (Pubitemid 351733418)
3. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 2010 28 19 3167 3175
4. Topalian S. L., Drake C. G., Pardoll D. M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Current Opinion in Immunology 2012 24 2 207 212
5. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Cells E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Medicine 2002 8 8 793 800
6. Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H., PD-1 and its ligands in tolerance and immunity Annual Review of Immunology 2008 26 677 704 (Pubitemid 351600389)
7. Matzinger P., Kamala T., Tissue-based class control: the other side of tolerance Nature Reviews Immunology 2011 11 3 221 230
8. Mhlbauer M., Fleck M., Schtz C., Weiss T., Froh M., Blank C., Schlmerich J., Hellerbrand C., PD-L1 is induced in hepatocytes by viral infection and by interferon- and- and mediates T cell apoptosis Journal of Hepatology 2006 45 4 520 528 (Pubitemid 44307379)
9. Pinchuk I. V., Saada J. I., Beswick E. J., Boya G., Qiu S. M., Mifflin R. C., Raju G. S., Reyes V. E., Powell D. W., PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4 + T-cell activity Gastroenterology 2008 135 4 1228 1237
10. Stanciu L. A., Bellettato C. M., Laza-Stanca V., Coyle A. J., Papi A., Johnston S. L., Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines Journal of Infectious Diseases 2006 193 3 404 412 (Pubitemid 43122340)
11. Latchman Y., Wood C. R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A. J., Brown J. A., Nunes R., Greenfield E. A., Bourque K., Boussiotis V. A., Carter L. L., Carreno B. M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A. H., Freeman G. J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nature Immunology 2001 2 3 261 268 (Pubitemid 33706004)
12. Kinter A. L., Godbout E. J., McNally J. P., Sereti I., Roby G. A., O'Shea M. A., Fauci A. S., The common -chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands Journal of Immunology 2008 181 10 6738 6746
13. Zhong X., Tumang J. R., Gao W., Bai C., Rothstein T. L., Rothstein T. L., PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding European Journal of Immunology 2007 37 9 2405 2410 (Pubitemid 47423611)
14. Messal N., Serriari N.-E., Pastor S., Nuns J. A., Olive D., PD-L2 is expressed on activated human T cells and regulates their function Molecular Immunology 2011 48 15-16 2214 2219
15. Lesterhuis W. J., Steer H., Lake R. A., PD-L2 is predominantly expressed by Th2 cells Molecular Immunology 2011 49 1-2 1 3
16. Okazaki T., Honjo T., PD-1 and PD-1 ligands: from discovery to clinical application International Immunology 2007 19 7 813 824 (Pubitemid 47241890)
17. Lesterhuis W. J., Punt C. J.A., Hato S. V., Eleveld-Trancikova D., Jansen B. J.H., Nierkens S., Schreibelt G., De Boer A., Van Herpen C. M.L., Kaanders J. H., Van Krieken J. H.J.M., Adema G. J., Figdor C. G., De Vries I. J.M., Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice Journal of Clinical Investigation 2011 121 8 3100 3108
18. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D. M., Okumura K., Azuma M., Yagita H., Expression of programmed death 1 ligands by murine T cells and APC Journal of Immunology 2002 169 10 5538 5545 (Pubitemid 35291652)
19. Rodig N., Ryan T., Allen J. A., Pang H., Grabie N., Chernova T., Greenfield E. A., Liang S. C., Sharpe A. H., Lichtman A. H., Freeman G. J., Endothelial expression of PD-L1 and PD-L2 down-regulates CD8 + T cell activation and cytolysis European Journal of Immunology 2003 33 11 3117 3126 (Pubitemid 37428344)
20. Nazareth M. R., Broderick L., Simpson-Abelson M. R., Kelleher R. J., Yokota S. J., Bankert R. B., Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells Journal of Immunology 2007 178 9 5552 5562 (Pubitemid 46674350)
21. Messal N., Serriari N.-E., Pastor S., Nuns J. A., Olive D., PD-L2 is expressed on activated human T cells and regulates their function Molecular Immunology 2011 48 15-16 2214 2219
22. Iwamura K., Kato T., Miyahara Y., siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Therapy. In press
23. Lesterhuis W. J., Steer H., Lake R. A., PD-L2 is predominantly expressed by Th2 cells Molecular Immunology 2011 49 1-2 1 3
24. Loke P., Allison J. P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proceedings of the National Academy of Sciences of the United States of America 2003 100 9 5336 5341 (Pubitemid 36542706)
25. Huber S., Hoffmann R., Muskens F., Voehringer D., Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2 Blood 2010 116 17 3311 3320
26. Hebenstreit D., Wirnsberger G., Horejs-Hoeck J., Duschl A., Signaling mechanisms, interaction partners, and target genes of STAT6 Cytokine and Growth Factor Reviews 2006 17 3 173 188 (Pubitemid 43816893)
27. Arima K., Watanabe N., Hanabuchi S., Chang M., Sun S. C., Liu Y. J., Distinct signal codes generate dendritic cell functional plasticity Science Signaling 2010 3 105 ra4
28. Diegelmann J., Olszak T., Gke B., Blumberg R. S., Brand S., A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins Journal of Biological Chemistry 2012 287 1 286 298
29. Chen H., Sun H., You F., Sun W., Zhou X., Chen L., Yang J., Wang Y., Tang H., Guan Y., Xia W., Gu J., Ishikawa H., Gutman D., Barber G., Qin Z., Jiang Z., Activation of STAT6 by STING is critical for antiviral innate immunity Cell 2011 147 2 436 446
30. Liang S. C., Latchman Y. E., Buhlmann J. E., Tomczak M. F., Horwitz B. H., Freeman G. J., Sharpe A. H., Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses European Journal of Immunology 2003 33 10 2706 2716 (Pubitemid 37337136)
31. Das J., Chen C. H., Yang L., Cohn L., Ray P., Ray A., A critical role for NF- B in GATA3 expression and T H 2 differentiation in allergic airway inflammation Nature Immunology 2001 2 1 45 50 (Pubitemid 33704952)
32. Gorski K. S., Shin T., Crafton E., Otsuji M., Rattis F. M., Huang X., Kelleher E., Francisco L., Pardoll D., Tsuchiya H., A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer Molecular Immunology 2003 40 1 35 47 (Pubitemid 36937059)
33. Thieu V. T., Nguyen E. T., McCarthy B. P., Bruns H. A., Kapur R., Chang C. H., Kaplan M. H., IL-4-stimulated NF- B activity is required for Stat6 DNA binding Journal of Leukocyte Biology 2007 82 2 370 379 (Pubitemid 47230649)
34. Lin D. Y. W., Tanaka Y., Iwasaki M., Gittis A. G., Su H. P., Mikami B., Okazaki T., Honjo T., Minato N., Garboczi D. N., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors Proceedings of the National Academy of Sciences of the United States of America 2008 105 8 3011 3016 (Pubitemid 351723659)
35. Lzr-Molnr E., Yan Q., Cao E., Ramagopal U., Nathenson S. G., Almo S. C., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10483 10488
36. Ghiotto M., Gauthier L., Serriari N., Pastor S., Truneh A., Nuns J. A., Olive D., PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1 International Immunology 2010 22 8 651 660
37. Youngnak P., Kozono Y., Kozono H., Iwai H., Otsuki N., Jin H., Omura K., Yagita H., Pardoll D. M., Chen L., Azuma M., Differential binding properties of B7-H1 and B7-DC to programmed death-1 Biochemical and Biophysical Research Communications 2003 307 3 672 677 (Pubitemid 36944985)
38. Ghiotto M., Gauthier L., Serriari N., Pastor S., Truneh A., Nuns J. A., Olive D., PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1 International Immunology 2010 22 8 651 660
39. Chemnitz J. M., Parry R. V., Nichols K. E., June C. H., Riley J. L., SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation Journal of Immunology 2004 173 2 945 954 (Pubitemid 38924267)
40. Parry R. V., Chemnitz J. M., Frauwirth K. A., Lanfranco A. R., Braunstein I., Kobayashi S. V., Linsley P. S., Thompson C. B., Riley J. L., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Molecular and Cellular Biology 2005 25 21 9543 9553 (Pubitemid 41507854)
41. Nurieva R., Thomas S., Nguyen T., Martin-Orozco N., Wang Y., Kaja M. K., Yu X. Z., Dong C., T-cell tolerance or function is determined by combinatorial costimulatory signals EMBO Journal 2006 25 11 2623 2633 (Pubitemid 44012244)
42. Riley J. L., PD-1 signaling in primary T cells Immunological Reviews 2009 229 1 114 125
43. Matsumoto K., Inoue H., Nakano T., Tsuda M., Yoshiura Y., Fukuyama S., Tsushima F., Hoshino T., Aizawa H., Akiba H., Pardoll D., Hara N., Yagita H., Azuma M., Nakanishi Y., B7-DC regulates asthmatic response by an IFN- -dependent mechanism Journal of Immunology 2004 172 4 2530 2541 (Pubitemid 38182404)
44. Ishiwata K., Watanabe N., Guo M., Tomihara K., Brumlik M. J., Yagita H., Pardoll D., Chen L., Shin T., Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis Journal of Immunology 2010 184 4 2086 2094
45. Wang S., Bajorath J., Flies D. B., Dong H., Honjo T., Chen L., Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction Journal of Experimental Medicine 2003 197 9 1083 1091 (Pubitemid 36570064)
46. Butte M. J., Keir M. E., Phamduy T. B., Sharpe A. H., Freeman G. J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 2007 27 1 111 122 (Pubitemid 47089023)
47. Zhang Y., Chung Y., Bishop C., Daugherty B., Chute H., Holst P., Kurahara C., Lott F., Sun N., Welcher A. A., Dong C., Regulation of T cell activation and tolerance by PDL2 Proceedings of the National Academy of Sciences of the United States of America 2006 103 31 11695 11700 (Pubitemid 44182513)
48. Salama A. D., Chitnis T., Imitola J., Akiba H., Tushima F., Azuma M., Yagita H., Sayegh M. H., Khoury S. J., Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis Journal of Experimental Medicine 2003 198 1 71 78 (Pubitemid 36870187)
49. Zhu B., Guleria I., Khosroshahi A., Chitnis T., Imitola J., Azuma M., Yagita H., Sayegh M. H., Khoury S. J., Differential role of programmed death-1 ligand and programmed death-2 ligand in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis Journal of Immunology 2006 176 6 3480 3489 (Pubitemid 43363995)
50. Fife B. T., Pauken K. E., The role of the PD-1 pathway in autoimmunity and peripheral tolerance Annals of the New York Academy of Sciences 2011 1217 1 45 59
51. Akbari O., Stock P., Singh A. K., Lombardi V., Lee W. L., Freeman G. J., Sharpe A. H., Umetsu D. T., DeKruyff R. H., PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions Mucosal Immunology 2010 3 1 81 91
52. Kanai T., Totsuka T., Uraushihara K., Makita S., Nakamura T., Koganei K., Fukushima T., Akiba H., Yagita H., Okumura K., Machida U., Iwai H., Azuma M., Chen L., Watanabe M., Blockade of B7-H1 suppresses the development of chronic intestinal inflammation Journal of Immunology 2003 171 8 4156 4163 (Pubitemid 37238692)
53. Ansari M. J. I., Salama A. D., Chitnis T., Smith R. N., Yagita H., Akiba H., Yamazaki T., Azuma M., Iwai H., Khoury S. J., Auchincloss H., Sayegh M. H., The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice Journal of Experimental Medicine 2003 198 1 63 69 (Pubitemid 36870186)
54. Keir M. E., Liang S. C., Guleria I., Latchman Y. E., Qipo A., Albacker L. A., Koulmanda M., Freeman G. J., Sayegh M. H., Sharpe A. H., Tissue expression of PD-L1 mediates peripheral T cell tolerance Journal of Experimental Medicine 2006 203 4 883 895
55. Shin T., Yoshimura K., Shin T., Crafton E. B., Tsuchiya H., Housseau F., Koseki H., Schulick R. D., Chen L., Pardoll D. M., In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses Journal of Experimental Medicine 2005 201 10 1531 1541 (Pubitemid 40720999)
56. Pfistershammer K., Klauser C., Pickl W. F., Stckl J., Leitner J., Zlabinger G., Majdic O., Steinberger P., No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation European Journal of Immunology 2006 36 5 1104 1113
57. Chen F., Liu Z., Wu W., Rozo C., Bowdridge S., Millman A., Van Rooijen N., Urban Jr. J. F., Wynn T. A., Gause W. C., An essential role for T H 2-type responses in limiting acute tissue damage during experimental helminth infection Nature Medicine 2012 18 2 260 266
58. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E. C., Su D., Marches F., Banchereau J., Palucka A. K., Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4 + T cells that facilitate tumor development Journal of Experimental Medicine 2007 204 5 1037 1047 (Pubitemid 46798148)
59. Pedroza-Gonzalez A., Xu K., Wu T.-C., Aspord C., Tindle S., Marches F., Gallegos M., Burton E. C., Savino D., Hori T., Tanaka Y., Zurawski S., Zurawski G., Bover L., Liu Y.-J., Banchereau J., Palucka A. K., Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation Journal of Experimental Medicine 2011 208 3 479 490
60. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di Carlo V., Doglioni C., Protti M. P., Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer Journal of Experimental Medicine 2011 208 3 469 478
61. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., Mizuno T., Yoriki R., Kashizuka H., Yane K., Tsushima F., Otsuki N., Yagita H., Azuma M., Nakajima Y., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clinical Cancer Research 2005 11 8 2947 2953 (Pubitemid 40525197)
62. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M., Nakajima Y., Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clinical Cancer Research 2007 13 7 2151 2157 (Pubitemid 46649885)
63. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T., Fujii S., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3360 3365 (Pubitemid 46364164)
64. Gao Q., Wang X. Y., Qiu S. J., Yamato I., Sho M., Nakajima Y., Zhou J., Li B. Z., Shi Y. H., Xiao Y. S., Xu Y., Fan J., Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clinical Cancer Research 2009 15 3 971 979
65. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., Saudemont A., Quesnel B., Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN- and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 2007 110 1 296 304 (Pubitemid 47026847)
66. Thompson R. H., Kuntz S. M., Leibovich B. C., Dong H., Lohse C. M., Webster W. S., Sengupta S., Frank I., Parker A. S., Zincke H., Blute M. L., Sebo T. J., Cheville J. C., Kwon E. D., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Research 2006 66 7 3381 3385
67. Curran M. A., Montalvo W., Yagita H., Allison J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4275 4280
68. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
69. Pilon-Thomas S., Mackay A., Vohra N., Mulé J. J., Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma Journal of Immunology 2010 184 7 3442 3449
70. Zhang L., Gajewski T. F., Kline J., PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood 2009 114 8 1545 1552
71. Parekh V. V., Lalani S., Kim S., Halder R., Azuma M., Yagita H., Kumar V., Wu L., Van Kaer L., PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells Journal of Immunology 2009 182 5 2816 2826
72. He Y. F., Zhang G. M., Wang X. H., Zhang H., Yuan Y., Li D., Feng Z. H., Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine Journal of Immunology 2004 173 8 4919 4928 (Pubitemid 39387773)
73. Okudaira K., Hokari R., Tsuzuki Y., Okada Y., Komoto S., Watanabe C., Kurihara C., Kawaguchi A., Nagao S., Azuma M., Yagita H., Miura S., Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model International Journal of Oncology 2009 35 4 741 749
74. Deal watch: GlaxoSmithKline and Amplimmune join forces on targeting PD1 Nature Reviews Drug Discovery 2010 9 10 754
75. Hobo W., Maas F., Adisty N., De Witte T., Schaap N., Van Der Voort R., Dolstra H., siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8 + T cells Blood 2010 116 22 4501 4511
76. Hato S. V., De Vries I. J., Lesterhuis W. J., STATing the importance of immune modulation by platinum chemotherapeutics OncoImmunology 2012 1 2 234 236
77. Lesterhuis W. J., Haanen J. B. A. G., Punt C. J. A., Cancer immunotherapy-revisited Nature Reviews Drug Discovery 2011 10 8 591 600
78. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapya practical partnership Nature Reviews Cancer 2005 5 5 397 405